Loading clinical trials...
Loading clinical trials...
A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6)
Conditions
Interventions
Durvalumab
Locations
28
United States
Research Site
Gainesville, Georgia, United States
Research Site
Knoxville, Tennessee, United States
Research Site
Créteil, France
Research Site
Paris, France
Research Site
Saint-Priest-en-Jarez, France
Research Site
Toulouse, France
Start Date
April 16, 2019
Primary Completion Date
December 13, 2022
Completion Date
April 21, 2023
Last Updated
June 18, 2024
NCT06476808
NCT07361497
NCT07510724
NCT06305754
NCT05920356
NCT06128551
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions